Transanal Minimally Invasive Surgery (TAMIS) for Local Excision of Benign Neoplasms and Early-stage Rectal Cancer

2013 ◽  
Vol 56 (3) ◽  
pp. 301-307 ◽  
Author(s):  
Matthew R. Albert ◽  
Sam B. Atallah ◽  
Teresa C. deBeche-Adams ◽  
Seema Izfar ◽  
Sergio W. Larach
Keyword(s):  
Rectal Cancer ◽  
Minimally Invasive Surgery ◽  
Minimally Invasive ◽  
Local Excision ◽  
Invasive Surgery ◽  
Early Stage ◽  
Benign Neoplasms ◽  
Transanal Minimally Invasive Surgery

Transanal Minimally Invasive Surgery (TAMIS): New Treatment for Early Rectal Cancer and Large Rectal Polyps—Experience of an Italian Center

2015 ◽  
Vol 81 (3) ◽  
pp. 273-277 ◽  
Author(s):  
Riccardo Maglio ◽  
Gallinella Marco Muzi ◽  
Massimo Meucci Massimo ◽  
Luigi Masoni
Keyword(s):  
Rectal Cancer ◽  
Minimally Invasive Surgery ◽  
Minimally Invasive ◽  
Local Excision ◽  
Invasive Surgery ◽  
Invasive Technique ◽  
Single Incision Laparoscopic Surgery ◽  
Early Rectal Cancer ◽  
Transanal Minimally Invasive Surgery ◽  
Laparoscopic Instruments

Transanal endoscopic microsurgery (TEM) is a minimally invasive technique for excision of rectal tumors that avoids conventional pelvic resectional surgery along with its risks and side effects. Although appealing, the associated cost and complex learning curve limit TEM use by colorectal surgeons. Transanal minimally invasive surgery (TAMIS) has emerged as an alternative to TEM. This platform uses ordinary laparoscopic instruments to achieve high-quality local excision. The aim of the study is to assess reliability of the technique. From July 2012 to August 2013, 15 consecutive patients with rectal pathology underwent TAMIS. After a single-incision laparoscopic surgery port was introduced into the anal canal, a pneumorectum was established with a laparoscopic device followed by transanal excision with conventional laparoscopic instruments, including graspers, electrocautery, and needle drivers. Patient demographics, operative data, and pathologic data were recorded. Of the 15 patients, 10 had rectal cancers (six T1 lesions and four T2 after preoperative chemoradiotherapy). The remainder of patients had a local excision for voluminous benign rectal adenomas. The median length of the lesions from the anal verge was 7 cm (range, 4 to 20 cm). The median operating time was 86 minutes (range, 33 to 160 minutes). There was no surgical morbidity or mortality. The median postoperative hospital stay was two days (range, 1 to 4 days). TAMIS seems to be a feasible and safe treatment option for early rectal cancer. We believe that this new technique is easy to perform, cost-effective, and less traumatic to the anal sphincter compared with traditional TEM.

The Role of TAMIS (Transanal Minimally Invasive Surgery) in the Management of Advanced Rectal Cancer – One Shared Story of Three Exceptional Cases

2018 ◽  
Vol 32 (4) ◽  
pp. 371-376 ◽  
Author(s):  
Dimitrios Giannoulopoulos ◽  
Constantinos Nastos ◽  
Maria Gavriatopoulou ◽  
Antonios Vezakis ◽  
Dionysios Dellaportas ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Minimally Invasive Surgery ◽  
Minimally Invasive ◽  
Invasive Surgery ◽  
Advanced Rectal Cancer ◽  
Transanal Minimally Invasive Surgery

scholarly journals Transanal Minimally Invasive Surgery: A Promising Alternative for Certain Advanced Rectal Cancer Patients

2018 ◽  
Vol 32 (4) ◽  
pp. 377-378 ◽  
Author(s):  
Hernan A. Sanchez-Trejo ◽  
Daniel Hakakian ◽  
Terrence Curran ◽  
Luca Antonioli ◽  
Balazs Csoka ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Minimally Invasive Surgery ◽  
Minimally Invasive ◽  
Cancer Patients ◽  
Invasive Surgery ◽  
Advanced Rectal Cancer ◽  
Transanal Minimally Invasive Surgery ◽  
Promising Alternative

scholarly journals Transanal minimally invasive surgery for rectal cancer

2020 ◽  
Author(s):  
Liam A. Devane ◽  
John P. Burke ◽  
Justin J. Kelly ◽  
Matthew R. Albert
Keyword(s):  
Rectal Cancer ◽  
Minimally Invasive Surgery ◽  
Minimally Invasive ◽  
Invasive Surgery ◽  
Transanal Minimally Invasive Surgery

scholarly journals Implementation of transanal minimally invasive surgery (TAMIS) for rectal neoplasms: results from a single centre

2021 ◽  
Author(s):  
W. Lossius ◽  
T. Stornes ◽  
T. E. Bernstein ◽  
A. Wibe
Keyword(s):  
Minimally Invasive Surgery ◽  
Minimally Invasive ◽  
Local Excision ◽  
Invasive Surgery ◽  
Rectal Neoplasms ◽  
Rectal Adenocarcinoma ◽  
Low Risk ◽  
University Hospital ◽  
Rectal Ulcer ◽  
Transanal Minimally Invasive Surgery

Abstract Background Local excisions are important in a tailored approach to treatment of rectal neoplasms. In cases of low risk T1 local excision facilitates rectal-preserving treatment. Transanal minimally invasive surgery (TAMIS) is the most recent alternative developed for local excision. In this study we evaluate the results after implementing TAMIS as the routine procedure for local excision of rectal neoplasms. Methods All patients who underwent TAMIS from January 2016 to January 2020 at St. Olav’s University Hospital were included, and clinical, pathological and oncological data were prospectively registered. The primary endpoint was local recurrence, and the secondary endpoint was complications. Results There were 76 patients (42 men, mean age was 69 years [range 26–88 years]), The mean tumour level was 82 mm (range 20–140 mm) from the anal verge measured on rigid proctoscopy, and mean tumour size was 32 mm (range 8–73 mm). Three patients experienced complications needing intervention (Clavien–Dindo > 3A). Seventeen patients had rectal adenocarcinoma, 9 of whom underwent R0 completion total mesorectal excision (cTME). Fifty-five patients had an adenoma, 3 of whom developed recurrence (5.4%) within 12 months. All recurrences were treated successfully with a new TAMIS procedure. In addition, TAMIS was used in treatment of 2 patients with a neuroendocrine tumour, 1 patient with a haemangioma and 1 patient with a solitary rectal ulcer. Conclusions TAMIS surgery is associated with a low risk of complications and a low recurrence rate in rectal neoplasms. In cases of adenocarcinoma, R0 cTME surgery is feasible in the sub-group with high risk T1 and T2 tumours.

Sign in / Sign up

Export Citation Format

Share Document